High-dose versus standard chemotherapy in metastatic breast cancer: Comparison of cancer and leukemia group B trials with data from the autologous blood and marrow transplant registry Academic Article Article uri icon

Overview

MeSH Major

  • Antineoplastic Combined Chemotherapy Protocols
  • Breast Neoplasms
  • Clinical Trials as Topic
  • Neoadjuvant Therapy
  • Neoplasm, Residual
  • Practice Guidelines as Topic

abstract

  • After controlling for known prognostic factors in this nonrandomized analysis of two large independent data sets, women receiving HDC versus SDC for metastatic breast cancer have a similar short-term probability of survival, and might have a modestly higher long-term probability of survival.

publication date

  • February 2002

Research

keywords

  • Academic Article

Identity

Digital Object Identifier (DOI)

  • 10.1200/JCO.20.3.743

PubMed ID

  • 11821456

Additional Document Info

start page

  • 743

end page

  • 50

volume

  • 20

number

  • 3